Biotech | August 10, 2021
Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
A veteran in cell therapy and oncology commercialisation
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The transaction is expected to close in the Q4FY22
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Subscribe To Our Newsletter & Stay Updated
